6 citations
,
December 2015 in “Journal of Dermatological Case Reports” Intradermal testing can better detect corticosteroid allergies than patch testing.
April 2019 in “The journal of investigative dermatology/Journal of investigative dermatology” Machine learning can predict how well patients with alopecia areata will respond to certain treatments.
June 2026 in “Current Oncology Reports” Sacituzumab Tirumotecan shows promise in treating gynecologic cancers with manageable side effects.
12 citations
,
March 2016 in “Life Sciences” The new chemotherapy combination of WP 631 and Epothilone B shows enhanced effectiveness against ovarian cancer but requires more research on its safety.
January 2025 in “Journal of the Egyptian Womenʼs Dermatologic Society” Higher substance P levels may cause discomfort in hair loss patients.
Upadacitinib effectively treated a patient with multiple inflammatory conditions.
52 citations
,
July 1998 in “Urology” Liarozole may be more effective than cyproterone acetate for treating advanced prostate cancer, with better PSA response and survival rates, while maintaining quality of life.
49 citations
,
February 2022 in “Drug Design Development and Therapy” Ritlecitinib shows promise for hair regrowth in alopecia areata patients.
February 2026 in “The Journal of Dermatology” Ritlecitinib effectively regrows scalp, eyebrow, and eyelash hair in Asians with alopecia areata and is safe.
March 2023 in “Biomedicine & Pharmacotherapy” GPR40 agonists help hair growth through the protein ANGPTL4.
January 2026 in “Dermatology Practical & Conceptual” Triamcinolone acetonide is more effective than cryotherapy for hair regrowth in alopecia areata but has different side effects.
September 2025 in “Journal of the American Academy of Dermatology” Some JAK inhibitors are effective for significant hair regrowth in alopecia areata.
June 2023 in “Fundamental & clinical pharmacology” JAK inhibitors help treat some diseases but may increase risks of blood clots and cancer in certain patients.
May 2025 in “Journal of the ASEAN Federation of Endocrine Societies” Early advanced therapies are crucial for better survival in aggressive insulinoma cases.
3 citations
,
April 2023 in “Frontiers in Pharmacology” ATP-sensitive K+ channel subunits, particularly Sur2A, play a significant role in various cancers.
5 citations
,
May 2020 in “Clinical and Experimental Dermatology” Clascoterone may be a promising treatment for hair loss.
June 2025 in “Indus journal of bioscience research.” Combining microneedling with triamcinolone acetonide is more effective for treating alopecia areata than microneedling alone.
23 citations
,
June 2019 in “Bioanalysis” Monitoring steroid hormones in blood can better detect testosterone doping.
January 2019 in “Oncogen” Triple Hormonal Blockade (ADT3) can effectively manage prostate cancer but requires careful monitoring for heart risks.
6 citations
,
December 2018 in “Ophthalmic Plastic and Reconstructive Surgery” Afatinib can cause eyelash and eyebrow issues, leading to eye irritation and pain.
11 citations
,
August 1997 in “Expert Opinion on Therapeutic Patents” Many potential alopecia treatments need more testing to confirm they promote acceptable hair growth with minimal side effects.
12 citations
,
June 2019 in “Psychoneuroendocrinology” Allopregnanolone is needed for certain brain processing issues caused by D1 dopamine receptor activation.
22 citations
,
November 2002 in “Clinical journal of oncology nursing” Arsenic trioxide effectively treats relapsed acute promyelocytic leukemia with manageable side effects.
September 2020 in “bioRxiv (Cold Spring Harbor Laboratory)” Finasteride may help reduce opioid use.
3 citations
,
December 2018 in “Biomedical and pharmacology journal/Biomedical & pharmacology journal” Compound 3 protects the heart from damage by activating A1-adenosine receptors.
20 citations
,
March 2005 in “Current Medicinal Chemistry” New compounds show promise for treating hair loss, enlarged prostate, and prostate cancer, with some being more effective and having different side effects than current treatments.
306 citations
,
August 2011 in “Journal of cachexia, sarcopenia and muscle” Enobosarm significantly increased muscle mass and improved physical function in elderly men and postmenopausal women without serious side effects.
April 2011 in “Cancer Research” 20(S)-Protopanaxadiol-aglycone may help prevent and treat prostate cancer by reducing androgen receptor activity.
January 2026 in “Zenodo (CERN European Organization for Nuclear Research)” LX-38 is a safer drug option for treating prostate issues and hair loss without hormonal side effects.
December 2025 in “Naunyn-Schmiedeberg s Archives of Pharmacology” Agomelatine may help reduce benign prostatic hyperplasia by blocking certain inflammatory pathways.